Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Erasca ( (ERAS) ) has issued an update.
On January 21, 2026, Erasca entered into an underwriting agreement with J.P. Morgan, Morgan Stanley, Jefferies and Evercore for an underwritten public offering of 22.5 million shares of common stock at $10.00 per share, with underwriters purchasing at $9.40 per share and holding a 30‑day option to buy up to an additional 3.375 million shares; the deal, expected to close on January 23, 2026, is anticipated to generate net proceeds of about $211 million, or $242.7 million if the option is fully exercised. The capital raise, announced via press releases on January 20 and 21, 2026 and conducted under an effective shelf registration, is intended to bolster Erasca’s funding for research and development of its oncology product candidates and broader corporate purposes, reinforcing its balance sheet to support ongoing clinical programs in RAS/MAPK pathway‑driven cancers and potentially strengthening its position in the competitive precision oncology landscape.
The most recent analyst rating on (ERAS) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.
Spark’s Take on ERAS Stock
According to Spark, TipRanks’ AI Analyst, ERAS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, heavy losses, and ongoing cash burn). Technicals are supportive due to a strong uptrend, but overbought signals raise near-term risk. Valuation remains challenged by negative earnings, partially offset by a positive corporate update showing accelerating clinical momentum and clear upcoming data catalysts.
To see Spark’s full report on ERAS stock, click here.
More about Erasca
Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway‑driven cancers. Co‑founded by pioneers in precision oncology and RAS targeting, the San Diego–based firm is developing novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway, aiming to address a range of difficult-to-treat cancers within this segment of the oncology market.
Average Trading Volume: 4,033,188
Technical Sentiment Signal: Buy
Current Market Cap: $2.78B
Find detailed analytics on ERAS stock on TipRanks’ Stock Analysis page.